Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2016 Jan;14(1):19-30.

Prostate Cancer, Version 1.2016.

Author information

1
Roswell Park Cancer Institute
2
Duke Cancer Institute
3
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
4
Dana-Farber/Brigham and Women’s Cancer Center
5
Mayo Clinic Cancer Center
6
Memorial Sloan Kettering Cancer Center
7
Fred & Pamela Buffett Cancer Center
8
Prostate Health Education Network (PHEN)
9
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
10
Fox Chase Cancer Center
11
Yale Cancer Center/Smilow Cancer Hospital
12
UC San Diego Moores Cancer Center
13
City of Hope Comprehensive Cancer Center
14
Massachusetts General Hospital Cancer Center
15
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
16
Vanderbilt-Ingram Cancer Center
17
Moffitt Cancer Center
18
University of Colorado Cancer Center
19
St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center
20
UCSF Helen Diller Family Comprehensive Cancer Center
21
University of California San Francisco Patient Services Committee Chair
22
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
23
University of Michigan Comprehensive Cancer Center
24
University of Alabama at Birmingham Comprehensive Cancer Center
25
Stanford Cancer Institute
26
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
27
Huntsman Cancer Institute at the University of Utah
28
National Comprehensive Cancer Network

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.

Comment in

PMID:
26733552
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center